SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response: 0.5

1. Name and Address of Reporting Person* Slover Peter T (Last) (First) (Middle) 3115 MERRYFIELD ROW (Street) SAN DIEGO CA 92121 (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 07/01/2009	3. Issuer Name and Ticker or Trading Symbol ANADYS PHARMACEUTICALS INC [ ANDS ]
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title below) Other (specify below) VP, Finance and Operations	5. If Amendment, Date of Original Filed (Month/Day/Year)
			6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	2,195(1)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	04/19/2005(2)	04/18/2014	Common Stock	2,500	$7.9	D
Stock Option (Right to Buy)	07/01/2005(3)	06/30/2014	Common Stock	2,000	$7.1	D
Stock Option (Right to Buy)	12/15/2005(4)	12/14/2014	Common Stock	1,850	$7	D
Stock Option (Right to Buy)	08/02/2006(5)	08/01/2015	Common Stock	3,375	$11.74	D
Stock Option (Right to Buy)	12/16/2006(6)	12/15/2015	Common Stock	2,500	$8.16	D
Stock Option (Right to Buy)	08/15/2007(7)	08/14/2016	Common Stock	10,000	$2.8	D
Stock Option (Right to Buy)	12/07/2007(8)	12/06/2016	Common Stock	5,000	$4.6	D
Stock Option (Right to Buy)	12/20/2006(9)	12/19/2016	Common Stock	2,000	$4.28	D
Stock Option (Right to Buy)	01/01/2008(10)	01/09/2017	Common Stock	15,000	$4.59	D
Stock Option (Right to Buy)	02/22/2008(11)	08/21/2017	Common Stock	22,500	$2.29	D
Stock Option (Right to Buy)	12/07/2008(12)	12/06/2017	Common Stock	10,000	$2	D
Stock Option (Right to Buy)	12/10/2009(13)	12/09/2018	Common Stock	30,000	$1.99	D
Stock Option (Right to Buy)	07/01/2010(14)	06/30/2019	Common Stock	50,000	$1.86	D

Explanation of Responses:

1. Includes the following shares acquired pursuant to the Anadys Pharmaceuticals, Inc. 2004 Employee Stock Purchase Plan: 670 shares acquired on May 15, 2006; 211 shares acquired on May 15, 2007; 437 shares acquired on November 15, 2007; 459 shares acquired on May 15, 2008; and 418 shares acquired on November 11, 2008.

2. 25% of the shares subject to the option became exercisable on April 19, 2005 with the remaining shares subject to the option vesting in equal monthly installments evenly over the next three year period such that all shares subject to the option became fully vested and exercisable as of April 19, 2008.

3. 25% of the shares subject to the option became exercisable on July 1, 2005 with the remaining shares subject to the option vesting in equal monthly installments evenly over the next three year period such that all shares subject to the option became fully vested and exercisable as of July 1, 2008.

4. 25% of the shares subject to the option became exercisable on December 15, 2005 with the remaining shares subject to the option vesting in equal monthly installments evenly over the next three year period such that all shares subject to the option became fully vested and exercisable as of December 15, 2008.

5. 25% of the shares subject to the option became exercisable on August 2, 2006 with the remaining shares subject to the option vesting in equal monthly installments evenly over the next three year period such that all shares subject to the option will be fully vested and exercisable as of August 2, 2009.

6. 25% of the shares subject to the option became exercisable on December 16, 2006 with the remaining shares subject to the option vesting in equal monthly installments evenly over the next three year period such that all shares subject to the option will be fully vested and exercisable as of December 16, 2009.

7. 25% of the shares subject to the option became exercisable on August 15, 2007 with the remaining shares subject to the option vesting in equal monthly installments evenly over the next three year period such that all shares subject to the option will be fully vested and exercisable as of August 15, 2010.

8. 25% of the shares subject to the option became exercisable on December 7, 2007 with the remaining shares subject to the option vesting in equal monthly installments evenly over the next three year period such that all shares subject to the option will be fully vested and exercisable as of December 7, 2010.

9. 25% of the shares subject to the option became exercisable on December 20, 2006 with the remaining shares subject to the option vesting in equal monthly installments evenly over the next three year period such that all shares subject to the option will be fully vested and exercisable as of December 20, 2009.

10. 25% of the shares subject to the option became exercisable on January 1, 2008 with the remaining shares subject to the option vesting in equal monthly installments evenly over the next three year period such that all shares subject to the option will be fully vested and exercisable as of January 1, 2011.

11. 25% of the shares subject to the option became exercisable on February 22, 2008 with the remaining shares subject to the option vesting in equal monthly installments evenly over the next two year period such that all shares subject to the option will be fully vested and exercisable as of August 22, 2009.

12. 25% of the shares subject to the option became exercisable on December 7, 2008 with the remaining shares subject to the option vesting in equal monthly installments evenly over the next three year period such that all shares subject to the option will be fully vested and exercisable as of December 7, 2011.

13. 25% of the shares subject to the option will become exercisable on December 10, 2009 with the remaining shares subject to the option vesting in equal monthly installments evenly over the next three year period such that all shares subject to the option will be fully vested and exercisable as of December 10, 2012.

14. 25% of the shares subject to the option will become exercisable on July 1, 2010 with the remaining shares subject to the option vesting in equal monthly installments evenly over the next three year period such that all shares subject to the option will be fully vested and exercisable as of July 1, 2013.

Remarks:

	/s/ Peter T Slover	07/09/2009
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.